Partnerships & Mergers

The partnership introduces a new model of care that combines advanced remote monitoring, post-discharge support, and hospital-at-home services, allowing patients to remain connected to healthcare professionals throughout their recovery journey.

The plan targets key pillars of outbreak control, including emergency coordination, disease surveillance, laboratory diagnostics, infection prevention and control, and clinical case management.

Under the new framework, Arcera Life Sciences will collaborate with M42 to harness genomics data and explore disease prevalence patterns across targeted genetic and rare conditions.

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

Through this arrangement, Pfizer aims to accelerate the identification and design of new therapeutic candidates, particularly in areas where traditional research methods have faced limitations.

Under the agreement, students and university staff will gain access to confidential digital psychological support sessions delivered through the Arab Therapy platform.

Ascidian will lead target discovery and selected preclinical activities, while Lilly will oversee additional preclinical development, clinical research, manufacturing, regulatory activities, and global commercialization.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.

The collaboration integrates Cercare Medical Neurosuite (CMN), a vendor-neutral imaging platform that provides automated perfusion analysis across CT, MRI, and Cone-Beam CT, with Siemens Healthineers’ Syngo DynaCT Multiphase system.

Researchers aim to assess the reliability of p-Tau217 in identifying early Alzheimer’s pathology and evaluate its potential as a scalable tool for long-term monitoring.